IPROOV
iProov , world leader in secure biometric authentication technology, today announced record-breaking growth in the first half of 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006091/en/
From January to June 2021, iProov saw a 15x increase in the number of people verified using its technology versus the same time period last year. Its flagship Genuine Presence Assurance technology solidified its global market leadership, with verifications growing at a consistent rate of 25% per month worldwide.
This has been driven by demand from organizations needing to verify the identity of online users to prevent fraud. iProov’s patented technology assures the genuine presence of an online user to ensure they are the right person, a real person, and authenticating right now.
iProov has been profitable in 2021, while at the same time growing its worldwide team by 25% to 85 staff. In April, the company welcomed cybersecurity veteran Paul King who joined iProov’s advisory board following 27 years at Cisco, most recently as Chief Security Officer. iProov has also been awarded numerous prestigious awards, including Best Biometric Solution at the 2021 Cyber Security Global Excellence Awards.
In what has been a tumultuous year across the globe, iProov’s technology has provided safe and secure digital identity verification for a growing range of vital services. Since the start of 2021, iProov has added major customers and partners to its portfolio spanning government, health, travel, financial services and ID providers.
In February iProov announced it had been selected by the Australian government to provide the liveness solution for myGovID. Millions of Australians will be able to strengthen their digital identity using a simple face scan on their mobiles, providing access to a range of government services, including online tax.
iProov’s existing service to NHS Digital in the UK became even more crucial this year. Since 2020, iProov has enabled users in England to create an NHS login remotely and securely. A user scans their identity document, such as a valid passport or driver’s license, and then completes a brief iProov face verification to confirm their identity, giving them secure access to the services of the NHS App. Since May 2021, this has included the COVID vaccination status service.
In January 2021, iProov announced a collaboration with its partner, Mvine, to trial private COVID status certificates. The solution enables an individual to register a test result or vaccination status and then securely share that status without disclosing their identity, using either paper or a smartphone. The trials, which took place in care and education settings, were backed by investment from Innovate UK and showcased how biometric verification could greatly simplify the checking of COVID status credentials while enhancing user privacy.
The iProov partner program grew by a third in the first six months of the year, from sectors including identity, health, travel and cryptocurrency. In April, Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, announced that it had selected iProov technology to deliver high conversion rates, fast onboarding, a natural user experience and small SDK size to its customers.
Andrew Bud, iProov Founder and CEO, commented: “In the first half of 2021, iProov has secured users’ identities online and protected major organizations from fraud on a vast scale across the globe. The dramatic acceleration in the digital identity market, caused by the pandemic, has demonstrated our market leadership based on our unrivaled usability, inclusiveness and resilient security, and the extraordinary scalability of our platform. I am continually impressed by the remarkable work of the iProov team in successfully rising to the many challenges created by such transformative growth.”
The highlights from 2021 so far include: -
Awards
● iProov Takes Home Gold in Three Cybersecurity Excellence Awards: Government, Financial Services, and Identity Proofing & Corroboration - https://www.iproov.com/blog/cyber-security-awards-government-finance
● iProov wins Best Biometric Solution at 2021 Cyber Security Global Excellence Awards - https://www.iproov.com/blog/best-biometric-solution-cyber-security-2021
● iProov Named Winner of Coveted Global InfoSec Award During RSA Conference - https://www.iproov.com/press/iproov-winner-of-global-infosec-award-during-rsa-conference-2021
Customers and partners
● Australian Taxation Office extends national digital identity program with face verification technology from iProov - https://www.iproov.com/press/australian-taxation-office-national-digital-identity-program-face-verification-technology
● Jumio adds iProov’s award winning liveness detection to its KYC platform - https://www.iproov.com/press/jumio-adds-iproov-award-winning-liveness-detection-to-its-kyx-platform
● iProov selected by itsme to support global expansion - https://www.iproov.com/press/iproov-face-verification-selected-by-itsme-to-support-global-expansion
● COVID-19 certificate solution from iProov and Mvine moves into trial phase - https://www.iproov.com/press/uk-covid19-passport-moves-into-trial-phase
Senior team hires
● Cybersecurity veteran Paul King joins iProov’s Advisory Board - https://www.iproov.com/press/cyber-security-veteran-joins-iproov-advisory-board
-ENDS-
About iProov
Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, financial institutions and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks that use deepfakes and other synthetic media. Supported by capital from private equity firm JRJ Group, iProov has grown a global footprint with offices in the UK, US and Singapore. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection and as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom